Market Closed -
Nasdaq
21:00:00 09/05/2024 BST
|
5-day change
|
1st Jan Change
|
8.95
USD
|
-3.97%
|
|
+6.67%
|
+231.48%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Capitalization
1 |
277.8
|
97.5
|
74.45
|
Enterprise Value (EV)
1 |
116.4
|
-25.58
|
-32
|
P/E ratio
|
-2.46
x
|
-2.13
x
|
-2.07
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
EV / FCF
|
-4,599,176
x
|
1,247,483
x
|
-9,244,691
x
|
FCF Yield
|
-0%
|
0%
|
-0%
|
Price to Book
|
1.64
x
|
0.76
x
|
0.7
x
|
Nbr of stocks (in thousands)
|
26,554
|
26,568
|
27,573
|
Reference price
2 |
10.46
|
3.670
|
2.700
|
Announcement Date
|
07/03/22
|
06/03/23
|
28/03/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.696
|
-11.77
|
-35.67
|
-45.14
|
-21.47
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-6.547
|
-20.67
|
-47.48
|
-45.24
|
-35.12
|
Net income
1 |
-6.547
|
-20.67
|
-47.48
|
-45.24
|
-35.12
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-4.450
|
-10.49
|
-4.244
|
-1.720
|
-1.301
|
Free Cash Flow
|
-
|
-6.57
|
-25.3
|
-20.51
|
3.462
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21/06/21
|
21/06/21
|
07/03/22
|
06/03/23
|
28/03/24
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.383
|
-10.7
|
-13.13
|
-13.7
|
-8.748
|
-9.554
|
-23.44
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-9.615
|
-10.54
|
-13.2
|
-14.6
|
-9.682
|
-7.762
|
-22.29
|
Net income
1 |
-10.94
|
-10.54
|
-13.2
|
-14.6
|
-9.682
|
-7.762
|
-22.29
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.7000
|
1.250
|
-0.5000
|
-0.5600
|
-0.3700
|
-0.2900
|
-0.8400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
08/11/21
|
07/03/22
|
16/05/22
|
15/08/22
|
14/11/22
|
06/03/23
|
11/05/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
21.2
|
20.5
|
161
|
123
|
106
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-6.57
|
-25.3
|
-20.5
|
3.46
|
ROE (net income / shareholders' equity)
|
-
|
-96.7%
|
-50.2%
|
-30.6%
|
-29.7%
|
ROA (Net income/ Total Assets)
|
-
|
-32%
|
-22.5%
|
-18.3%
|
-10.9%
|
Assets
1 |
-
|
64.67
|
210.7
|
247.2
|
321.3
|
Book Value Per Share
2 |
-3.350
|
-7.310
|
6.370
|
4.840
|
3.880
|
Cash Flow per Share
2 |
12.80
|
5.990
|
1.790
|
1.640
|
3.360
|
Capex
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21/06/21
|
21/06/21
|
07/03/22
|
06/03/23
|
28/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +231.48% | 261M | | +2.97% | 108B | | +10.21% | 105B | | +1.57% | 23.46B | | -12.77% | 21.72B | | -7.05% | 18.64B | | -37.64% | 17.45B | | -6.50% | 17.19B | | +6.00% | 13.99B | | +37.20% | 12.53B |
Bio Therapeutic Drugs
|